Actively Recruiting
Mindful-Breath for People With COPD
Led by The University of Hong Kong · Updated on 2025-09-29
60
Participants Needed
1
Research Sites
99 weeks
Total Duration
On this page
Sponsors
T
The University of Hong Kong
Lead Sponsor
H
Health and Medical Research Fund
Collaborating Sponsor
AI-Summary
What this Trial Is About
Individuals living with chronic obstructive pulmonary disease (COPD) often suffer from stress and behavioral risks such as physical inactivity. In an attempt to promote healthy behaviors and overall wellbeing among this particular population, this study aims to develop and evaluate a personalized Mindful-Breath intervention combining telehealth technology and mindfulness for COPD patients. This is an assessor-blinded, two-arm exploratory randomized controlled trial with a sequential mixed-method design. A total of 60 participants will be recruited and randomly assigned to either intervention or control group using 1:1 ratio. Intervention group will go through 8 weekly 60-min hybrid group sessions, combining mindfulness-based pulmonary rehabilitation and lifestyle modification. Personalized mindfulness-based lifestyle counselling through instant messages with chat-based support throughout the 8-week intervention period will also be provided. Control group will receive a single in-person 60-min group session on general education on pulmonary rehabilitation and lifestyle modification and will only receive reminder messages for follow-ups. Variables such as time spent on physical activity, lung function, perceived stress, symptom burden and health-related quality of life will be collected at three time-points (T0: baseline, prior to randomization; T1: immediate post-intervention; T2: 3-month post-intervention).
CONDITIONS
Official Title
Mindful-Breath for People With COPD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 50 and 80 years
- Male or female
- Education level of primary school or above
- Diagnosis of COPD with Baseline FEV1 <80% and FEV1/FVC <70% of predicted normal values
- COPD severity stage I to IV
- COPD group B or E based on 2024 GOLD guideline
- Clinically stable with no acute exacerbation in the past 4 weeks
- Moderate stress with PSS score ≥14
- Access to a mobile device with internet connectivity (smartphone, tablet, or laptop)
- Ability to read, communicate, and provide written consent in Chinese
You will not qualify if you...
- Engaging in more than 60 minutes per week of moderate physical activity
- Participation in other pharmacological or behavioral trials within the past 3 months
- Contraindications or severe comorbidities limiting participation (mental diseases, deafness, limb activity disorder, coronary heart disease, arterial aneurysm, uncontrolled hypertension, pregnancy, etc.)
- Co-existing respiratory diseases such as asthma, interstitial lung disease, bronchiectasis, or active malignancies
- Very severe COPD requiring long-term oxygen therapy or home non-invasive ventilation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
School of Nursing, The University of Hong Kong, Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
J
Jojo Yan Yan Kwok
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here